The effect of nicardipine on glucose and drug-stimulated insulin secretion in normal volunteers.
The effect of nicardipine on insulin secretion was examined in two double-blind, randomised, cross-over, placebo-controlled studies in normal volunteers. In the first study, the effect of acute dosing (via an intravenous infusion of 5 mg h-1 for 3 h) on the glucose, insulin, hormonal, and intermediary metabolite responses to an intravenous glucose tolerance test was determined in six healthy male volunteers. In the second study, the glucose, insulin, and C-peptide responses to intravenous tolbutamide (200 mg) was determined in another six male volunteers after oral dosing with nicardipine 30 mg three times daily for 1 week. A relative increase in insulin secretion was the principal finding of the first study. No other response was affected significantly. No significant differences between the nicardipine- and placebo-treated groups were noted in the insulin, glucose, and C-peptide measurements of the second study. In conclusion, treatment with nicardipine does not appear to impair insulin secretion in response either to an intravenous glucose load or intravenously administered tolbutamide.
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D005947:Glucose / Q000494:pharmacology*; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D008297:Male; D009529:Nicardipine; D009543:Nifedipine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014044:Tolbutamide / Q000494:pharmacology
D001786:Blood Glucose; D002096:C-Peptide; D002121:Calcium Channel Blockers; D007328:Insulin; D014044:Tolbutamide; D009529:Nicardipine; D009543:Nifedipine; D005947:Glucose